Clinical Trials Directory

Trials / Completed

CompletedNCT06318117

Reason for Prescribing Rice Infant Formula

Observational Study on the Use of Infant Formulas Based on Rice Protein Hydrolysate in Real Life Conditions

Status
Completed
Phase
Study type
Observational
Enrollment
41 (actual)
Sponsor
Mead Johnson Nutrition · Industry
Sex
All
Age
6 Months – 36 Months
Healthy volunteers
Accepted

Summary

The main purpose of this study is to describe the pattern of RIF consumption in real life conditions, whatever the reasons of initiation and the chosen formula. The main objective is to study the reasons for prescribing a RIF during the first year of life, as per the pediatrician. Consumption started before 6 months of age, when milk and infantile formulas predominates in the baby's feeding, is of particular interest.

Detailed description

The main purpose of this study is to describe the pattern of RIF consumption in real life conditions, whatever the reasons of initiation and the chosen formula. The main objective is to study the reasons for prescribing a RIF during the first year of life, as per the pediatrician. Consumption started before 6 months of age, when milk and infantile formulas predominates in the baby's feeding, is of particular interest. Secondary objectives are to describe the modalities of feeding before, during and after consuming the RIF, to describe the growth of children who have consumed a RIF for at least 1 month, on the basis of anthropometric data collected during the first year of life. As a second intention, this study also aims to monitor the evolution of child's digestive and allergic symptoms, if any, and the sociodemographic characteristics of the infant's family.

Conditions

Interventions

TypeNameDescription
OTHERRice infant formulaAny commercially available rice infant formula whom the pediatrician has previously deemed, or is deeming it useful to consume.

Timeline

Start date
2024-03-12
Primary completion
2025-10-31
Completion
2025-12-31
First posted
2024-03-19
Last updated
2026-01-30

Locations

17 sites across 1 country: France

Source: ClinicalTrials.gov record NCT06318117. Inclusion in this directory is not an endorsement.